Targeting the Oncogenic LARP1/DKK4/β‐catenin Axis in Hepatoblastoma

Fuda Xie,Bonan Chen,Wing Sum Shin,Jun Yu,Ka Fai To,Wei Kang

DOI: https://doi.org/10.1002/ctd2.210

2023-01-01

Clinical and Translational Discovery

Abstract:Hepatoblastoma (HB) is a rare primary malignancy but ranks as the most common type of malignant liver cancer that occurs in the first 5 years of neonates.1 A considerable proportion of patients with HB are faced with rapid progression characterised by multiple nodules at diagnosis, vascular invasion, chemoresistance and relapse.2 Although a combined therapy, including surgery and neoadjuvant chemotherapy, could significantly improve the overall survival rate of HB patients, approximately 30% of patients still experience relatively poor prognosis.3 Meanwhile, the early diagnosis for HB is intractable due to the ambiguity of the aetiology and the lack of serum biomarkers.4 Thus, it is still urgent to identify the underlying pathogenesis to achieve a better prognosis for HB patients. In this issue of Clinical and Translational Medicine, Cui et al. identified a novel regulatory cascade that may play a vital role in the progression of HB.5 In this work, they discussed the O-GlcNAcylation on a specific oncogene, namely La-related protein 1 (LAPR1), and elucidated the mechanism of the abnormal activation of LARP1 and the following tumour-promoting LARP1/DKK4/β-catenin cascade in HB carcinogenesis. LARP1 is a protein that belongs to the La superfamily and plays essential roles in various aspects of RNA metabolism, including mRNA translation, stability and splicing. The overexpression of LARP1 has been identified in multiple types of cancers with oncogenic functions (Table 1). The tumour-promoting effect of LARP1 is mediated by its regulatory function on mRNA translation. Specifically, LARP1 could bind to the 5′ untranslated region of target mRNAs, facilitating their translation by recruiting the translation initiation factor eukaryotic translation initiation factor 4E (eIF4E) to the m7G cap structure at the 5′ end of the mRNA.6 Other translation factors, such as poly(A)-binding protein (PABP) and eukaryotic translation initiation factor 4G (eIF4G), were also demonstrated to be associated with LARP1 in mRNA translation promotion.7 These interactions would significantly increase the stability and enrichment of mRNAs encoding for proteins involved in tumour cell proliferation and migration, such as c-Myc, cyclin D1 and Bcl-2.8, 9 Post-translational modifications of proteins, including phosphorylation, methylation and ubiquitination, are commonly observed and would play important roles in protein functioning and metabolism. Adding O-linked β-N-acetylglucosamine (O-GlcNAc) to the serine and threonine residues of proteins, known as O-GlcNAcylation, is a universal post-translational modification that could alter the functions and stabilities of proteins involved in various biological processes and diseases.18 Recent studies suggest that O-GlcNAcylation would play a significant role in the occurrence, growth, metastasis, drug resistance and cancer stem cell population maintenance of another liver cancer: hepatocellular carcinoma (HCC).19, 20 The principal oncogenic function of O-GlcNAcylation is revealed by the induction of proteins with abnormal behaviours or stimulus-responsiveness in HCC progression. In Cui's work, they proved that the Ser672 residue of LARP1 is O-GlcNAc-modified by O-GlcNAc transferase (OGT) in HB progression, which leads to LARP1 stabilisation to avoid ubiquitin-proteasome-mediated degradation. Moreover, several circRNAs have been demonstrated to play critical roles in the upregulation of LARP1.15, 21 The authors also revealed that the binding of circCLNS1A to LARP1 can protect LARP1 from ubiquitination and proteolysis by competing with the degradation mediator tripatite motif containing 25 (TRIM-25). These findings delineated the mechanism of the abnormal upregulation of LARP1 and provided potential strategies for targeting this oncogenic alteration. The Wnt/β-catenin signalling pathway is a well-known oncogenic pathway proven guilty of the malignancy and heterogeneity of numerous types of cancers. The core regulatory pattern of the canonical Wnt pathway is the binding of Wnt ligands with fizzed proteins (FZDs) as well as LRP5/6 downregulating the phosphorylation and degradation of β-catenin. As a result, accumulated active β-catenin triggers the nuclear translocation and activates the T-cell factor/lymphoid enhancer factor (TCF/LEF) transcript factor, leading to the upregulation of genes associated with tumour cell proliferation, migration and stemness maintenance.22 In Cui's work, a non-canonical activator of Wnt/β-catenin signalling, namely dickkopf-related protein 4 (DKK4), was found to be upregulated along with LARP1. Through deeper investigation, the authors revealed that the competitive interaction between LARP1 and PABPC1, an important RNA-binding protein for initiating protein translation and mRNA decay, would lead to the stabilisation of DKK4 mRNA though preventing its BTG2-dependent deadenylation and degradation. By illuminating the underlying LARP1-DKK4-β-catenin cascade in HB progression, this work provoked interest in LARP1/DKK4 targeting therapies as promising strategies for HB treatment. Even though the oncogenic function of DKK4 has been concreted in several studies, some evidence also suggests that DKK4 also possesses tumour suppressive functions in specific circumstances. The Dickkopf proteins (DKKs) are generally recognised as antagonists of the Wnt signalling pathway for the prevention function of the Kremen-mediated Wnt-FZDs-LRP5/6 complex formation.23 Although the role of DKK4 is relatively controversial and less studied, the LRP5/6-binding and Wnt signalling-inhibiting capability of DKK4 has been proved, and the tumour suppressive potential of DKK4 was observed in HCC and lung cancer.24, 25 However, it could promote tumour progression by activating other non-canonical Wnt signallings, and the carcinogenic effect of DKK4 has been proven in various other cancer types. It can serve as a prognostic factor predicting poor prognosis and accelerate tumour cell progression in vitro and in vivo.26 Interestingly, DKK4-deletion was demonstrated effective in enhancing colon tumour cells' sensitivity towards chemotherapies.27 As a regulator of canonical and non-canonical Wnt pathways with a dual role in carcinogenesis, DKK4 could be involved in multiple regulatory routines on β-catenin nuclear accumulation. In summary, the development of DKK4-targeted drugs can be promising but torturous. Meanwhile, once launched, these drugs still need to be applied accurately and precisely based on the tumour types and the molecular background of the tumours.